Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Zeo ScientifiX ( (ZEOX) ) is now available.
On April 9, 2026, ZEO ScientifiX, Inc. announced it had signed a memorandum of understanding with Regen Therapy to become the exclusive partner for biologic research, development, and manufacturing on Regen’s regenerative medicine platform. Under the deal, ZEO is positioned as the core supplier of advanced biologic therapeutics, including extracellular vesicle, perinatal-derived and acellular signaling technologies, for integration into Regen’s nationwide clinical ecosystem.
The MOU coincides with Regen Therapy’s separate partnership with Stealth Health and integration of the Metabolic Code precision health system, together creating a vertically integrated network spanning more than 3,000 U.S. clinics and 24,000 practitioners. By embedding telemedicine, licensed prescribers, pharmacy fulfillment and data-driven longevity programs into brick-and-mortar practices, the collaborations aim to scale personalized regenerative and longevity care, strengthen ZEO’s role in the fast-growing longevity market, and provide clinics with new revenue streams and access to scientifically advanced biologic products.
More about Zeo ScientifiX
ZEO ScientifiX, Inc. (OTCQB: ZEOX) is a clinical-stage biopharmaceutical company specializing in the development and cGMP-compliant manufacturing of advanced biologic therapeutics. The company focuses on regenerative medicine through scientific innovation, rigorous research, and scalable product development to support next-generation therapies in longevity and human performance.
Average Trading Volume: 6,095
Technical Sentiment Signal: Buy
Current Market Cap: $15.71M
See more data about ZEOX stock on TipRanks’ Stock Analysis page.